RxDoctor Payments Data

David Gilbert, MD

Ophthalmology · Walnut Creek, CANPI 1033297536

Payments from drug & device makers

$2,559in general payments, 2019–2025

Across 71 payments — averaging $36.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alcon$740
  • Oyster Point Pharma, Inc.$234
  • Nevro Corp.$81
  • Thea Pharma Inc.$59
  • Sun Pharmaceutical Industries Inc.$51
  • plus $161 from 8 others

What the payments were for

  • Travel & lodging$120%
  • Food & beverage$2,52799%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,559 in reported general payments places this provider in the 60th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$854,121
Medicare patients
1,802
Services billed
5,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost110$67,200
RestasisCyclosporine47$58,212
Prednisolone Acetate372$25,677
Cyclosporine34$18,388
Latanoprost1,294$18,147
RhopressaNetarsudil Mesylate32$16,558
CombiganBrimonidine Tartrate/Timolol24$13,211
SimbrinzaBrinzolamide/Brimonidine Tart28$11,957
Brinzolamide59$10,342
Brimonidine Tartrate204$9,345
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat368$8,535
Alphagan PBrimonidine Tartrate22$8,200
Timolol Maleate380$6,508
MoxifloxacinMoxifloxacin Hcl339$6,247
VyzultaLatanoprostene Bunod16$5,984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$1,234$146,824203 claims
AlconSimbrinza$740$11,95728 claims
Bausch & Lomb Americas Inc.Vyzulta$41$5,98416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Walnut Creek

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →